Melvin D. Booth and Dean L. Hubbard, Ph.D. Join Ventria’s Board of Directors
Ventria Bioscience, a privately held biopharmaceutical company that is leading the development of plant-made pharmaceuticals, announced today that Melvin D. Booth, former President of MedImmune, and Dean L. Hubbard, Ph.D., President of Northwest Missouri State University, have joined the company’s Board of Directors.
Maryville, MO (PRWEB via PR Web
Direct) January 28, 2005 -- Ventria Bioscience, a privately held
biopharmaceutical company that is leading the development of plant-made
pharmaceuticals, announced today that Melvin D. Booth, former President of
MedImmune, and Dean L. Hubbard, Ph.D., President of Northwest Missouri State
University, have joined the company’s Board of Directors.
Mr. Booth has
over 25 years of experience in the biotechnology and pharmaceutical industries.
He was President and Chief Operating Officer of MedImmune Inc. (NASDAQ: MEDI)
for five years and currently serves on MedImmune’s Board of Directors. Prior to
joining MedImmune, Mr. Booth was President and Chief Operating Officer of Human
Genome Sciences (NASDAQ: HGSI) and also served on the Board of Directors. In
addition, he has served as Chairman of the Pharmaceutical Manufacturers
Association of Canada.
“I am greatly impressed by Ventria’s product
pipeline and underlying technology, which will make a major contribution to
human health on a global scale,” said Mr. Booth. “Ventria is leading the way in
developing innovative technologies that enable the production of a broad number
of human health products and I am excited to be a part of this innovative
company. “
Dr. Hubbard has been the President of Northwest Missouri
State University since 1984 and has been a leading force in the creation of the
Center of Excellence in Plant-made Pharmaceuticals. Under Dr. Hubbard’s
leadership, Northwest has received national attention for its “Culture of
Quality” to improve the quality of all aspects of the institution’s operations.
Dr. Hubbard is internationally recognized for his work in the field of total
quality management. Dr. Hubbard received his Ph.D. from Stanford University and
holds additional degrees from Yonsei University and Andrews University.
“I am honored to join Ventria’s board of directors,” said Dr. Hubbard.
“As part of realizing our vision for the Center of Excellence in Plant-made
Pharmaceuticals at Northwest Missouri State University, I look forward to the
collaboration we have established with Ventria and Missouri’s farmers. This
collaboration will develop the necessary infrastructure to convert this
technology from lab bench to product success for the benefit of the global
community.”
“We are very pleased to have Mr. Booth and Dr. Hubbard join
Ventria’s Board of Directors,” said Thomas N. Urban, Jr. Chairman of Ventria’s
Board of Directors. “Their vision for creating the Center of Excellence in
Plant-made Pharmaceuticals and their expertise will accelerate the
commercialization of Ventria’s product pipeline and establishes Ventria as the
leader in plant-made pharmaceuticals,” he said.
Ventria Bioscience is
commercializing products that enhance human health and save lives. One of
Ventria’s products is an improved oral rehydration solution. Oral rehydration
solutions are administered to children with acute diarrhea, a condition that
claims the lives of 1.3 million children under the age of five on an annual
basis.
For more information, see our website at Ventria Bioscience http://www.ventria.com.
Or contact:
Brandy Sargent
Corporate Communications
e-mail protected from spam bots
(916)
921-6148
# # #
Source : http://www.prweb.com/releases/2005/1/prweb203014.htm